Avience Biomedicals Summary
The business operation revolves around the manufacture, supply, and exportation of molecular diagnostic products related to biotechnology, genomics, and IVD. Expansion within the product portfolio includes a range from IVD test kits to medical equipment covering serology products and biochemistry analyzers. Hence, this highlights the diverse needs within health care with a strict focus on the business markets, B2B, and B2G. Avience provides different kinds of diagnostic tools, which include but not limited to, rapid test kits such as AVISURE Dengue Combo Test, Malaria Rapid Test, and AVISURE Syphilis Rapid Test; biochemistry analyzer and reagent such as BS-240 Fully Auto Analyzer and AVIENBIO Albumin Kit; molecular diagnosis products like COVID-19 test kits; hematology analyzers such as BC-20s 3-Part Hematology Analyzer; medical devices such as oxygen concentrator like Oxy-5 and Oxy-10, and viral transport medium (VTM). These products utilize both B2B and B2G sales channels for marketing to Pathology Labs, Microbiology Labs, Hospitals, and Research Centers domestically and abroad. Apart from manufacturing, the company also works as distributors and traders of medical equipment.
Talking about the process involved in business operations, the company conducts all its activities by means of use of the manufacturing unit that operates in Noida, Uttar Pradesh, where the molecular diagnostic solutions, rapid test kits, biochemistry analyzers, hematology equipment, and medical devices are manufactured. The company serves many clients who belong to different categories such as Pathology Labs, Microbiology Labs, Hospitals, and Research Centers in India and outside India. In any case, there will not arise any difficulty in generating a constant stream of income for the company due to the following reasons; the company manufactures many types of diagnostic products like rapid test kits, analyzers, hematology equipment, and molecular kits, has an effective distribution network in India and abroad, offers affordable solutions, has a good quality control system adhering to ISO guidelines, and possesses experience and expertise in the field of diagnostics.
NSE SME book-built issue by Avience Biomedicals Limited, wherein face value is ₹10 per share with the price band of ₹196.00–₹208.00 per share. Issue size of ₹30.24 Cr, out of which the new issue is of ₹28.53 Cr, and Market Maker portion is ₹1.71 Cr. Issue is bifurcated between QIBs including Anchor, NII, and Retail Investors, and tentative listing of the stock will be on NSE SME on 25th June 2026.
Avience Biomedicals IPO Details:
Avience Biomedicals Limited Issue Management:
Fintellectual Corporate Advisors Pvt.Ltd. acts as the book-running lead manager for Avience Biomedical's NSE SME IPO, managing underwriting and compliance.
Avience Biomedicals Limited IPO RTA (Registrar) Details:
Skyline Financial Services Pvt.Ltd. handles allotment, refunds, and demat credits - contact at 02228511022 or ipo@skylinerta.com.
Avience Biomedicals Limited IPO Allotment Status:
To check your IPO allotment status:
Visit the Skyline Financial Services Pvt.Ltd. IPO Application Status page.
Select the company name from the dropdown menu.
Select and enter PAN, Application Number, DP/Client ID, or Account Number/IFSC.
Click Submit to view your allotment status.
Avience Biomedical's SME IPO totals ₹30.24 Cr, comprising a fresh issue of ₹28.53 Cr and ₹1.71 Cr reserved for the market maker. The face value is ₹10 per share and the price band is ₹196.00–₹208.00 per share (book-built issue on NSE SME).
Avience Biomedicals Limited IPO proceeds from the fresh issue will be deployed towards:
Avience Biomedicals IPO offers 14,53,800 equity shares (total issue ₹30.24 Cr, net offer to public 13,71,600 shares after market-maker reservation).
The anchor bidding for Avience Biomedicals Limited SME IPO is scheduled one working day before the issue opens on 18th June 2026 (i.e., 17th June 2026), and anchor investors will be allotted shares from the QIB portion (within the overall QIB tranche, as per SME-IPO structure). As per the IPO reservation details, the QIB portion (including anchor) accounts for about 49.83% of the net issue size, with anchor investors getting 28.19% of net issue (4,09,800 shares) and the remainder QIB (ex-anchor) getting 18.82% (2,73,600 shares). The NII (HNI) portion is 15.09% (with bNII > ₹10L getting 9.49% and sNII < ₹10L getting 4.75%) and the Retail portion is 35.08%.
Lock-in: The anchor allocation follows standard SME IPO norms, where 50% of the anchor shares are locked in for 30 days and the remaining 50% for 90 days from the listing date. The issue is scheduled to list on 25th June 2026 on NSE SME.
The anchor allocation details and investor list will be disclosed in the anchor book before the IPO opening. Fintellectual Corporate Advisors Pvt.Ltd. is the Book Running Lead Manager (BRLM) to the issue, and the registrar for the IPO is Skyline Financial Services Pvt.Ltd.
The profit realized from the production and sales made by Avience Biomedicals Limited involves molecular diagnostics solutions such as the rapid tests kits, biochemistry analyzers, hematology analyzers, and molecular kit services for Pathology Labs, Microbiology Labs, Hospitals, and Research Centers. The profit realized by the company arises from the sales of AVISURE Dengue Combo Test, Malaria Rapid Test, AVISURE Syphilis Rapid Test, BS-240 Fully Auto Analyzer, AVIENBIO Albumin Kit, COVID-19 Hid RTqPCR ASSAY, BC-20s 3-Part Hematology Analyzer, Oxy-5 & Oxy-10 oxygen concentrators, and VTM viral transport media, among other products.
When it comes to the performance perspective regarding finance, it can be said that the organization has performed well in terms of increasing total income. This increase is depicted from the fact that its Total Income has been ₹24.37 crore for FY24, ₹45.97 crore for FY25, and ₹41.94 crore (for 10 months ending Jan 2026). Another important factor relating to the firm's profitability is Profit After Tax (PAT), which was ₹2.14 crore for FY24, ₹7.23 crore for FY25, and ₹5.74 crore (for 10 months ending Jan 2026). With regard to EBITDA, it stood at ₹4.08 crore for FY24, ₹11.41 crore for FY25, and ₹10.34 crore (for 10 months ending Jan 2026). It is important to note here that the margin was favorable as the EBITDA and PAT margins were 24.70% and 15.86% (Jan 2026). The Return on Equity (ROE) and Return on Capital Employed (ROCE) of the firm were 22.38% and 16.99%, respectively (Jan 2026). In terms of the firm's net worth, it increased from ₹6.21 crore in FY24 to ₹22.78 crore in FY25, and ₹28.52 crore (Jan 2026).
Action Links:
To apply for Avience Biomedicals Limited IPO, open a demat account here
Avience Biomedicals Limited IPO Subscription Status: Check live subscription here
Avience Biomedicals Limited IPO GMP Update: Check latest grey market premium here
Avience Biomedicals Key Highlights:
Avience Biomedicals Limited is involved in producing molecular diagnostic kits that include rapid tests, analyzers, hematology instruments, and molecular kits. Some of the products produced by Avience are AVISURE Dengue Combo Test, Malaria Rapid Test (Pf/Pv), AVISURE Syphilis Rapid Test, BS-240 Fully Auto Analyzer, AVIENBIO Albumin Kit, COVID-19 Hid RTqPCR ASSAY, BC-20s 3-Part Hematology Analyzer, Oxy-5 and Oxy-10 oxygen concentrators, and VTM viral transport media. The organization also serves as distributors and traders of medical equipment.
Avience Biomedicals Limited’s main strengths are its vast industry knowledge and experience, diverse range of diagnostics products such as rapid test kits, analyzers, hematology equipment, and molecular kits, wide distribution network in India and increasingly in other countries as well, affordable solutions, strict quality control measures according to ISO standards, and 98 employees as of December 2024 (65 permanent and 33 contractual).
Financial performance of the firm is indicated by its Total Income of ₹24.37 crore in FY24, ₹45.97 crore in FY25, and ₹41.94 crore for 10 months ending Jan 2026. Its PAT is ₹2.14 crore in FY24, ₹7.23 crore in FY25, and ₹5.74 crore for January 2026. The EBITDA was ₹4.08 crore in FY24, ₹11.41 crore in FY25, and ₹10.34 crore in January 2026. Its margins are at 24.70% (EBITDA) and 15.86% (PAT), respectively. ROE and ROCE are at 22.38% and 16.99%, respectively, in Jan 2026. Net worth of the firm has seen a substantial increase to ₹22.78 crore in FY25, and ₹28.52 crore (Jan 2026).
Avience Biomedicals Risk Factors:
The risks of Avience Biomedicals Limited IPO are mentioned below:
Dependencies on Biotechnology and IVD Industry: Dependencies on Pathology Labs, Microbiology Labs, Hospitals, and orders from Research Centers. A decline in health sector activity will have a negative impact on revenue.
Price Fluctuations of Critical Raw Materials: Dependency on raw materials used in the manufacture of diagnostic products. Price fluctuations in raw material costs may result in a significant negative impact on profits.
Risk of Regulatory Compliances: Manufacturing diagnostic products involves regulatory compliances with ISO and medical device standards. Non-compliance may result in risk.
Liquidity Risk due to SME Listing at NSE: The listing of the business in NSE SME with a share issuance of ₹30.24 Cr and market capitalization of ₹114.09 Cr poses risks to liquidity.
Increased Levels of Borrowings: Increase in borrowings of ₹26.73 crore in January 2026 (₹22.16 crore in FY25 and ₹15.13 crore in FY24).
Risks faced by Promoters’ Share due to Post-IPO Dilution: After the IPO process, the stake held by promoters in the company will decrease by 23.30% from its current value of 87.89% to 64.59%.
Risk involved in execution of capex: Proposed capex of ₹15.96 Cr for establishment of new manufacturing unit in Medical Device Park, YEIDA, Uttar Pradesh faces risks related to effective utilization of capacity and generation of returns on investment.
Working Capital Risk: Proposed amount of ₹8.25 Cr to be used as working capital requires a high amount of working capital.
Risk due to customer concentration: Depending on Pathology Labs, Microbiology Labs and Hospitals; government projects would lead to delayed payments or even order cancellation.
Presence of Competitors in Diagnostics Products Business: Presence of competitors in the diagnostics and medical devices business may affect our market share.
Avience Biomedicals Expert Analysis:
Avience Biomedicals' SME IPO (NSE SME) is a book-built issue with a price band of ₹196.00–₹208.00 per share (face value ₹10). The total issue size is ₹30.24 Cr, comprising a fresh issue of ₹28.53 Cr and ₹1.71 Cr reserved for the market maker. The IPO is structured for QIB (49.83% including anchor), NII (15.09% with bNII > ₹10L getting 9.49% and sNII < ₹10L getting 4.75%), and Retail (35.08%) investors, with the tentative listing on NSE SME on 25th June 2026.
Basic details of the IPO:
Type of IPO: Book‑built SME IPO (NSE SME)
Uses of funds: Capital expenditure for new manufacturing unit at Medical Device Park, YEIDA, Uttar Pradesh (₹15.96 Cr), Working capital requirements (₹8.25 Cr), General corporate purposes (₹4.32 Cr)
Anchor bidding: 17th June 2026 | Opens 18th June 2026 | Closes 22nd June 2026 | Allotment 23rd June 2026 | Listing 25th June 2026 (NSE SME).
Lead Manager: Fintellectual Corporate Advisors Pvt.Ltd. | Registrar: Skyline Financial Services Pvt.Ltd.
Expert View on the IPO:
This niche firm is engaged in the production of molecular diagnostics kits such as Rapid test kits, Analyzers, Hematology machines, and Molecular Kits for use by Pathology Labs, Microbiology Labs, Hospitals, and Research Centers. Such products offer healthy profitability (PAT of ₹5.74 Cr for 10 Months ended January 2026 vs ₹2.14 Cr in FY24, indicating a growing trend in profitability). The stock currently offers an earnings multiple of 11.59x (pre-IPO) and 16.56x (post-IPO) along with P/B Valuation Multiple of 2.94x. Return on Equity and Return on Capital Employed (ROCE) stand at 22.38% and 16.99%, respectively, (January 2026), with PAT margin being at 15.86% and EBITDA margin at 24.70%. Some of the problems faced by the firm are cyclical nature of Biotechnology/IVD industry, regulatory risks, heavy debt load of ₹26.73 Cr, liquidity constraints associated with SME listing, promoter dilution from 87.89% to 64.59%, and capex risk pertaining to the new facility construction at Medical Device Park, YEIDA (₹15.96 Cr).
Should you invest in Avience Biomedicals?
An investor looking for a biotechnology and molecular diagnostics manufacturing company listed on the SME board, with growth trajectory in the IVD sector, moderate ROE (22.38%) and ROCE (16.99%), and exposure to India's healthcare and diagnostic sector might find the IPO of Avience Biomedicals interesting provided that he can handle SME listing limitations, raw material price volatility, regulatory compliance, high debt burden, and promoter dilution.
Consider investing when:
It would be necessary to get exposure to manufacturing molecular diagnostic solutions such as Rapid Test Kits, Analyzers, Hematology Equipment, Molecular Kits targeted towards Pathology Labs, Microbiology Labs, Hospitals, and Research Centers where ROE is 22.38% and ROCE is 16.99%.
There is no problem in respect of any risk on account of liquidity problem of small-cap stocks listed in market, fluctuation of prices of raw materials, compliance of regulation, high debt burden of company i.e. ₹26.73 Crore, and dilution by promoters (23.30%).
You may rest assured that management would utilize the funds raised from public offer in capital expenditure i.e. establishing new manufacturing facility in Medical Device Park at YEIDA, Uttar Pradesh (₹15.96 Crore) and working capital requirement (₹8.25 Crore).
Growth potential is bright in the coming days owing to development of healthcare facilities, diagnostic testing and governmental support in the healthcare sector.
Do not invest when:
Your investments should be made in firms within the biotechnology and diagnostics products industry that engage in diversified raw material hedging, more than one manufacturing facility, and have fewer debt liabilities.
Speaking of risks, your concerns would revolve around liquidity risk in SME stocks, risk of non-compliance to laws, heavy borrowings (₹26.73 Crore), and risks of promoter dilution.
Promoter dilution (87.89% to 64.59%) following the initial public offering, risk of execution capex for the new plant, and customer concentration risk in Pathology labs and hospitals will suit you.
Organizations which will suit your profile include those which have low valuations (P/E < 11), low debt/equity ratios, or strong market position.
Investors are advised to exercise discretion and refer to the full DRHP/RHP document before reaching any investment decision. This analysis is for informative purposes and not investment advice.
Action Links:
To apply for Avience Biomedicals Limited IPO, open a demat account here
Avience Biomedicals Limited IPO Subscription Status: Check live subscription here
Avience Biomedicals Limited IPO GMP Update: Check latest grey market premium here
1. What is the Avience Biomedicals Limited IPO open and close date?
Avience Biomedicals SME IPO opens on 18th June 2026 and closes on 22nd June 2026. The tentative listing date on NSE SME is 25th June 2026.
Track Avience Biomedicals Limited IPO subscription status live here from Finnpick.
2. What is the Avience Biomedicals Limited IPO price band and lot size?
The IPO is a book-built SME issue with a price band of ₹196.00–₹208.00 per share (face value ₹10). The minimum bid for retail investors is 1,200 shares (2 lots), with subsequent bids in multiples of 600 shares. Minimum investment is ₹2,49,600.
3. What is Avience Biomedicals Limited IPO total size?
The total issue size is ₹30.24 Cr, comprising a fresh issue of ₹28.53 Cr and ₹1.71 Cr reserved for the market maker. The net offer to the public is 13,71,600 shares (6,83,400 to QIB including 4,09,800 anchor, 2,07,000 to NII, 4,81,200 to Retail), after excluding 82,200 shares for Market Maker.
4. How to apply for the Avience Biomedicals Limited IPO?
Open a demat here (Zerodha/Upstox/AngelOne) or apply ASBA by June 22, 4 PM. Monitor Avience Biomedicals Limited IPO subscription tracker here. Ensure your demat account is active and UPI mandate is approved before the closing time.
5. How to check Avience Biomedicals Limited IPO Allotment Status?
The allotment date is on June 23rd and can be checked on Skyline Financial Services Pvt.Ltd. RTA portal using PAN/DP ID.
6. What is Avience Biomedicals Limited IPO GMP today and subscription status?
Current Grey Market Premium (GMP) stands at ₹50 as of June 15, indicating listing at the price range of ₹258 - check daily updates of Avience Biomedicals Limited IPO GMP trends here and live subscription status here from June 18th opening only on Finnpick.
7. What does Avience Biomedicals Limited specialize in?
Avience Biomedicals is engaged in manufacturing molecular diagnostic solutions, including rapid test kits (AVISURE Dengue Combo Test, Malaria Rapid Test, AVISURE Syphilis Rapid Test), biochemistry analyzers and reagents (BS-240 Fully Auto Analyzer, AVIENBIO Albumin Kit), molecular diagnostics (COVID-19 Hid RTqPCR ASSAY), hematology analyzers (BC-20s 3-Part Hematology Analyzer), and medical devices (Oxy-5 and Oxy-10 oxygen concentrators, VTM viral transport solutions). The company also acts as distributors and traders of medical equipment, serving Pathology Labs, Microbiology Labs, Hospitals, and Research Centers across India and overseas. The manufacturing unit is situated in Noida, Uttar Pradesh, with 98 employees (65 permanent + 33 contractual) as of December 2024.
8. When is the Avience Biomedicals Limited IPO listing date?
The IPO is scheduled to list on NSE SME on 25th June 2026, subject to final confirmation from the exchange. Basis of allotment is tentatively on 23rd June 2026, with refunds and demat credits around 24th June 2026.
9. What are the Avience Biomedicals Limited IPO proceeds utilization details?
The IPO proceeds will primarily be utilized towards: Capital expenditure for new manufacturing unit at Medical Device Park, YEIDA, Uttar Pradesh: ₹15.96 Cr, Working capital requirements: ₹8.25 Cr, General corporate purposes: ₹4.32 Cr
10. Who are the promoters of Avience Biomedicals Limited?
The promoters of Avience Biomedicals Limited are Mr. Dharam Deo Choudhary, Mr. Ram Nagina Choudhary, Mr. Janardan Pal, and Ms. Deepa Choudhary. Pre-IPO promoter holding is 87.89%, which will dilute to 64.59% post-IPO (23.30% dilution).
11. Should I apply for the Avience Biomedicals IPO?
You may consider applying if you are comfortable with an SME-listed biotechnology and molecular diagnostics manufacturing business (rapid test kits, analyzers, hematology devices, molecular kits) with growth trajectory in the IVD sector, moderate ROE (22.38%) and ROCE (16.99%), and exposure to India's healthcare and diagnostic sector. Avoid if you are risk-averse to SME listing liquidity constraints, raw material price volatility, regulatory compliance risks, high borrowings (₹26.73 Crore), significant promoter dilution (23.30%), and capex execution risk for new facility at Medical Device Park, YEIDA (₹15.96 Crore). This is for informational purposes only and not investment advice; read the RHP/DRHP and consult a SEBI-registered advisor before investing.
